Plus deals involving BiomX/Adapative Phage, One/NEX-I, Shionogi/FunPep, Taiho/Haihe, Kinnate/Pierre Fabre, StemCell Technologies/SQZ and more, as well as tech transfer agreements.

Ryvu Therapeutics has added to its drug discovery collaborators with an early-stage deal with Belgium’s Galapagos. 

A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.

Pre-IPO Bridge Biotherapeutics inks major idiopathic pulmonary fibrosis license agreement with Boehringer Ingelheim, marking the biggest single product licensing out deal by a South Korean biotech. The move is poised to further bolster the German firm's leading position in the field and reflects global pharma's increasing interest in IPF.